vs
Madison Square Garden Entertainment Corp.（MSGE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Madison Square Garden Entertainment Corp.的1.8倍（$772.1M vs $424.8M），Madison Square Garden Entertainment Corp.净利率更高（21.8% vs 12.7%，领先9.1%），Madison Square Garden Entertainment Corp.同比增速更快（12.5% vs 5.9%），过去两年Madison Square Garden Entertainment Corp.的营收复合增速更高（48.9% vs 9.0%）
麦迪逊广场花园娱乐公司是总部位于美国纽约的体育控股企业，依托麦迪逊广场花园的核心资源，在体育赛事运营、体育IP管理及相关商业化领域拥有深厚行业积累与广泛影响力。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MSGE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$424.8M
营收增速更快
MSGE
高出6.6%
5.9%
净利率更高
MSGE
高出9.1%
12.7%
两年增速更快
MSGE
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $424.8M | $772.1M |
| 净利润 | $92.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 38.6% | 14.5% |
| 净利率 | 21.8% | 12.7% |
| 营收同比 | 12.5% | 5.9% |
| 净利润同比 | 22.2% | 3.9% |
| 每股收益（稀释后） | $1.94 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSGERVTY
| Q4 25 | $424.8M | $772.1M | ||
| Q3 25 | $154.1M | $698.9M | ||
| Q2 25 | $145.1M | $720.3M | ||
| Q1 25 | $206.0M | $664.8M | ||
| Q4 24 | $377.6M | $729.4M | ||
| Q3 24 | $134.1M | $684.0M | ||
| Q2 24 | $177.6M | $691.7M | ||
| Q1 24 | $191.6M | $649.9M |
净利润MSGERVTY
| Q4 25 | $92.7M | $98.4M | ||
| Q3 25 | $-21.7M | $46.7M | ||
| Q2 25 | $-27.2M | $53.9M | ||
| Q1 25 | $8.0M | $42.2M | ||
| Q4 24 | $75.9M | $94.6M | ||
| Q3 24 | $-19.3M | $94.4M | ||
| Q2 24 | $66.9M | $55.4M | ||
| Q1 24 | $2.8M | $26.0M |
毛利率MSGERVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MSGERVTY
| Q4 25 | 38.6% | 14.5% | ||
| Q3 25 | -19.3% | 11.7% | ||
| Q2 25 | -17.7% | 12.6% | ||
| Q1 25 | 13.3% | 10.9% | ||
| Q4 24 | 36.8% | 16.3% | ||
| Q3 24 | -13.8% | 14.3% | ||
| Q2 24 | -5.0% | 12.4% | ||
| Q1 24 | 8.8% | 6.8% |
净利率MSGERVTY
| Q4 25 | 21.8% | 12.7% | ||
| Q3 25 | -14.0% | 6.7% | ||
| Q2 25 | -18.7% | 7.5% | ||
| Q1 25 | 3.9% | 6.4% | ||
| Q4 24 | 20.1% | 13.0% | ||
| Q3 24 | -14.4% | 13.8% | ||
| Q2 24 | 37.7% | 8.0% | ||
| Q1 24 | 1.5% | 4.0% |
每股收益（稀释后）MSGERVTY
| Q4 25 | $1.94 | $0.86 | ||
| Q3 25 | $-0.46 | $0.40 | ||
| Q2 25 | $-0.56 | $0.46 | ||
| Q1 25 | $0.17 | $0.35 | ||
| Q4 24 | $1.56 | $0.77 | ||
| Q3 24 | $-0.40 | $0.77 | ||
| Q2 24 | $1.32 | $0.45 | ||
| Q1 24 | $0.06 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.1M | $919.9M |
| 总债务越低越好 | $554.6M | — |
| 股东权益账面价值 | $36.0M | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 15.40× | — |
8季度趋势，按日历期对齐
现金及短期投资MSGERVTY
| Q4 25 | $157.1M | $919.9M | ||
| Q3 25 | $29.9M | $931.4M | ||
| Q2 25 | $43.0M | $991.8M | ||
| Q1 25 | $89.0M | $1.1B | ||
| Q4 24 | $54.9M | $1.2B | ||
| Q3 24 | $37.3M | $1.2B | ||
| Q2 24 | $33.3M | $2.0B | ||
| Q1 24 | $28.0M | $1.7B |
总债务MSGERVTY
| Q4 25 | $554.6M | — | ||
| Q3 25 | $581.7M | — | ||
| Q2 25 | $568.8M | — | ||
| Q1 25 | $577.4M | — | ||
| Q4 24 | $584.7M | — | ||
| Q3 24 | $647.0M | — | ||
| Q2 24 | $599.2M | — | ||
| Q1 24 | $602.5M | — |
股东权益MSGERVTY
| Q4 25 | $36.0M | $7.3B | ||
| Q3 25 | $-65.8M | $7.4B | ||
| Q2 25 | $-13.3M | $7.6B | ||
| Q1 25 | $9.5M | $7.6B | ||
| Q4 24 | $10.3M | $7.7B | ||
| Q3 24 | $-48.7M | $7.9B | ||
| Q2 24 | $-23.2M | $7.9B | ||
| Q1 24 | $-94.6M | $7.8B |
总资产MSGERVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.5B | $13.4B |
负债/权益比MSGERVTY
| Q4 25 | 15.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 60.61× | — | ||
| Q4 24 | 56.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流MSGERVTY
| Q4 25 | $164.4M | $182.0M | ||
| Q3 25 | $19.8M | $138.5M | ||
| Q2 25 | $-27.0M | $134.3M | ||
| Q1 25 | $56.8M | $128.2M | ||
| Q4 24 | $112.9M | $174.2M | ||
| Q3 24 | $-27.4M | $147.9M | ||
| Q2 24 | $212.0K | $158.6M | ||
| Q1 24 | $5.8M | $147.6M |
自由现金流MSGERVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率MSGERVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度MSGERVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率MSGERVTY
| Q4 25 | 1.77× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 7.07× | 3.03× | ||
| Q4 24 | 1.49× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 0.00× | 2.87× | ||
| Q1 24 | 2.08× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSGE
| Ticketing And Venue License Fee Revenues | $263.5M | 62% |
| Food Beverage And Merchandise Revenues | $64.3M | 15% |
| Related Party | $43.9M | 10% |
| Arena Licensing Fees And Other Leasing Revenue | $35.2M | 8% |
| Other | $15.9M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
